{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:33:40Z","timestamp":1792103620489,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:00:00Z","timestamp":1684627200000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:46:08Z","timestamp":1653079568000},"page":"82-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Recent advances in demystifying the metabolism of lipoprotein(a)"],"prefix":"10.1016","volume":"349","author":[{"given":"K\u00e9vin","family":"Chemello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00041433-199506000-00005","article-title":"Structure and metabolism of lipoprotein (a)","volume":"6","author":"Marcovina","year":"1995","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.ATV.13.5.758","article-title":"Comparison of ligand-binding sites of modeled apo[a] kringle-like sequences in human lipoprotein[a]","volume":"13","author":"Guevara","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/bi00455a007","article-title":"Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA","volume":"29","author":"Koschinsky","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/hmg\/2.7.933","article-title":"Molecular definition of the extreme size polymorphism in apolipoprotein(a)","volume":"2","author":"Lackner","year":"1993","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"van der Hoek","year":"1993","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CS20160403","article-title":"The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies","volume":"131","author":"Lambert","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI113849","article-title":"Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis","volume":"83","author":"Kraft","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0009-3084(94)90131-7","article-title":"Intracellular processing of apo(a) in primary baboon hepatocytes","volume":"67\u201368","author":"White","year":"1994","journal-title":"Chemistry and Physics of Lipids"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib15","doi-asserted-by":"crossref","first-page":"32403","DOI":"10.1074\/jbc.271.50.32403","article-title":"The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells","volume":"271","author":"Brunner","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib16","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1021\/bi972761t","article-title":"Intracellular metabolism of human apolipoprotein(a) in stably transfected hep G2 cells","volume":"37","author":"Lobentanz","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-2275(20)33367-8","article-title":"Presecretory degradation of apolipoprotein[a] is mediated by the proteasome pathway","volume":"40","author":"White","year":"1999","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib19","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1016\/S0021-9258(17)37076-X","article-title":"Molecular basis for \u201cnull\u201d lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon","volume":"269","author":"White","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib20","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0022-2275(20)32192-1","article-title":"Inhibition of N-linked glycosylation results in retention of intracellular apo[a] in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro","volume":"39","author":"Bonen","year":"1998","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0021-9258(19)40146-4","article-title":"Abetalipoproteinemia with an ApoB-100-lipoprotein(a) glycoprotein complex in plasma. Indication for an assembly defect","volume":"265","author":"Menzel","year":"1990","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0005-2760(79)90131-0","article-title":"Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B","volume":"575","author":"Krempler","year":"1979","journal-title":"Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1172\/JCI109813","article-title":"Turnover of lipoprotein (a) in man","volume":"65","author":"Krempler","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib25","doi-asserted-by":"crossref","first-page":"24369","DOI":"10.1016\/S0021-9258(18)35775-2","article-title":"Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a)","volume":"267","author":"Chiesa","year":"1992","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib26","doi-asserted-by":"crossref","first-page":"24284","DOI":"10.1016\/S0021-9258(19)51079-1","article-title":"Expression of human apolipoprotein B90 in transgenic mice. Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein","volume":"269","author":"McCormick","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib27","doi-asserted-by":"crossref","first-page":"206S","DOI":"10.1042\/bst022206s","article-title":"Apolipoprotein-a in human liver is not associated with apolipoprotein-B","volume":"22","author":"Munro","year":"1994","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib28","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0022-2275(20)39785-6","article-title":"Apolipoprotein[a] is not associated with apolipoprotein B in human liver","volume":"35","author":"Wilkinson","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib29","doi-asserted-by":"crossref","first-page":"28716","DOI":"10.1016\/S0021-9258(19)61964-2","article-title":"Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes","volume":"269","author":"White","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib30","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1074\/jbc.272.9.5659","article-title":"Expression of a recombinant apolipoprotein(a) in HepG2 cells: EVIDENCE for intracellular assembly OF LIPOPROTEIN(a)","volume":"272","author":"Bonen","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib31","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1074\/jbc.273.28.17793","article-title":"Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion","volume":"273","author":"Nassir","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib32","doi-asserted-by":"crossref","unstructured":"A. Youssef, J.R. Clark, S.M. Marcovina, M.B. Boffa, M.L. Koschinsky, ApoA and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) (Lipoprotein[a]) Levels by Modulation of ApoB Secretion, Arteriosclerosis, Thrombosis, and Vascular Biology. 0 (n.d.) ATVBAHA.121.317335. https:\/\/doi.org\/10.1161\/ATVBAHA.121.317335.","DOI":"10.1161\/ATVBAHA.121.317335"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib33","doi-asserted-by":"crossref","first-page":"15471","DOI":"10.1074\/jbc.270.26.15471","article-title":"A two-step model for lipoprotein(a) formation (\u2217)","volume":"270","author":"Trieu","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib34","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.ATV.16.12.1559","article-title":"Lipoprotein(a) assembly. Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation","volume":"16","author":"Gabel","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1399-0004.1997.tb04351.x","article-title":"Analysis of the mechanism of lipoprotein(a) assembly","volume":"52","author":"Koschinsky","year":"1997","journal-title":"Clin Genet"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib36","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/01.ATV.18.11.1738","article-title":"Sequences within the amino terminus of ApoB100 mediate its noncovalent association with apo(a)","volume":"18","author":"Gabel","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib37","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1021\/bi973186w","article-title":"Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100","volume":"37","author":"Gabel","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib38","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/protein\/11.12.1249","article-title":"Expression of apolipoprotein(a) kringle IV type 9 in Escherichia coli: demonstration of a specific interaction between kringle IV type 9 and apolipoproteinB-100","volume":"11","author":"Rahman","year":"1998","journal-title":"Protein Eng"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10238-001-8022-3","article-title":"Effect of low-density lipoprotein buoyant density and cholesterol content on the formation of lipoprotein(a) particles","volume":"1","author":"Becker","year":"2001","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/01.ATV.0000055741.13940.15","article-title":"A synthetic peptide that inhibits lipoprotein(a) assembly","volume":"23","author":"Sharp","year":"2003","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib41","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.1016\/S0021-9258(19)36587-1","article-title":"Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100","volume":"268","author":"Koschinsky","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib42","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1073\/pnas.90.24.11643","article-title":"Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly","volume":"90","author":"Brunner","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-5793(94)00737-3","article-title":"Carboxyl-terminal truncation of apolipoproteinB-100 inhibits lipoprotein(a) particle formation","volume":"350","author":"Gabel","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib44","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1172\/JCI118203","article-title":"Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a)","volume":"96","author":"Callow","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib45","doi-asserted-by":"crossref","first-page":"23616","DOI":"10.1074\/jbc.272.38.23616","article-title":"Transgenic mice expressing human ApoB95 and ApoB97. Evidence that sequences within the carboxyl-terminal portion of human apoB100 are important for the assembly of lipoprotein","volume":"272","author":"McCormick","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib46","doi-asserted-by":"crossref","first-page":"28195","DOI":"10.1074\/jbc.M002772200","article-title":"An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a)","volume":"275","author":"Cheesman","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib47","doi-asserted-by":"crossref","first-page":"9919","DOI":"10.1021\/bi060283t","article-title":"Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation","volume":"45","author":"Becker","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0021-9150(00)00732-2","article-title":"The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans","volume":"157","author":"Demant","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2012.09.031","article-title":"In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)","volume":"225","author":"Frischmann","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.plipres.2017.09.001","article-title":"The renaissance of lipoprotein(a): brave new world for preventive cardiology?","volume":"68","author":"Ellis","year":"2017","journal-title":"Progress in Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib51","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib52","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.metabol.2019.04.010","article-title":"Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration","volume":"96","author":"Ma","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nature Reviews Cardiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib55","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib56","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1042\/bj20030932","article-title":"Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism","volume":"376","author":"Hrzenjak","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib58","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","article-title":"Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation","volume":"38","author":"Kronenberg","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib59","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI119055","article-title":"Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine","volume":"98","author":"Mooser","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-8981(00)00394-6","article-title":"Urinary excretion of apolipoprotein(a): relation to other plasma proteins","volume":"304","author":"Kostner","year":"2001","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib62","first-page":"121","article-title":"Urinary apo(a) excretion is not altered by changes in glomerular filtration rate and renal plasma flow in healthy males","volume":"112","author":"Kostner","year":"2000","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib64","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib65","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1194\/jlr.M038877","article-title":"Scavenger receptor-BI is a receptor for lipoprotein(a)","volume":"54","author":"Yang","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib66","first-page":"408","article-title":"SCARB1 gene variants are associated with the phenotype of combined high high-density lipoprotein cholesterol and high lipoprotein (a)","volume":"9","author":"Yang","year":"2016","journal-title":"Circulation: Cardiovascular Genetics"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib67","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","article-title":"Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a)","volume":"120","author":"Sharma","year":"2017","journal-title":"Circulation Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib68","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-2275(20)37595-7","article-title":"Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2","volume":"37","author":"Tam","year":"1996","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib69","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/ki.1997.503","article-title":"Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease: rapid Communication","volume":"52","author":"Trenkwalder","year":"1997","journal-title":"Kidney International"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib70","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor","volume":"100","author":"Argraves","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib71","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.ATV.19.3.552","article-title":"Identification of megalin\/gp330 as a receptor for lipoprotein(a) in vitro","volume":"19","author":"Niemeier","year":"1999","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib72","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0022-2275(20)37140-6","article-title":"Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein","volume":"38","author":"Reblin","year":"1997","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-5793(93)81087-G","article-title":"Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein\/\u03b12-macroglobulin receptor","volume":"325","author":"M\u00e4rz","year":"1993","journal-title":"FEBS Letters"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(88)81406-6","article-title":"In vivo studies on the binding sites for lipoprotein (a) on parenchymal and non-parenchymal rat liver cells","volume":"227","author":"Harkes","year":"1988","journal-title":"FEBS Letters"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib75","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-2275(20)42633-1","article-title":"Interaction of lipoprotein Lp[a] with the B\/E-receptor: a study using isolated bovine adrenal cortex and human fibroblast receptors","volume":"31","author":"Steyrer","year":"1990","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180869","article-title":"Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin\/kexin type 9","volume":"12","author":"Romagnuolo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib77","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib78","article-title":"Statin therapy increases lipoprotein(a) levels","author":"Tsimikas","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib79","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable Atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(81)81153-2","article-title":"Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts","volume":"132","author":"Havekes","year":"1981","journal-title":"FEBS Letters"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0021-9258(18)48499-2","article-title":"Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages","volume":"267","author":"Snyder","year":"1992","journal-title":"Journal of Biological Chemistry"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2022.04.002_bib82","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5551\/jat1994.2.Supplement1_S1","article-title":"Cellular binding and degradation of lipoprotein (a)","volume":"2","author":"Fless","year":"1995","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib83","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-2275(20)43165-7","article-title":"Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor","volume":"31","author":"Armstrong","year":"1990","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib84","first-page":"1101","article-title":"Interaction of Lp(a) and of apo(a) with liver cells, Arterioscler","volume":"13","author":"Kostner","year":"1993","journal-title":"Thromb"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib85","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/S0022-2275(20)30026-2","article-title":"LDL-mediated interaction of Lp[a] with HepG2 cells: a novel fluorescence microscopy approach","volume":"38","author":"Hofer","year":"1997","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib86","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib87","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib88","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1016\/S0021-9258(18)52913-6","article-title":"Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation","volume":"268","author":"Bottalico","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib89","first-page":"419","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib90","first-page":"549","article-title":"Lipoprotein(a) cellular uptake ex vivo and hepatic capture In vivo is Insensitive to PCSK9 inhibition with alirocumab","volume":"5","author":"Chemello","year":"2020","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib91","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous FH patients with identical mutations variably express the LDL receptor: implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib92","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI114602","article-title":"Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice","volume":"85","author":"Hofmann","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib93","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1021\/bi00088a022","article-title":"Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator","volume":"32","author":"Liu","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib94","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci (Lond)."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib95","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.ejhg.5200152","article-title":"Concentrations of the atherogenic Lp(a) are elevated in familial hypercholesterolaemia: a sib pair and family analysis","volume":"6","author":"Lingenhel","year":"1998","journal-title":"European Journal of Human Genetics"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib96","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib97","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1172\/JCI119402","article-title":"Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB","volume":"99","author":"van der Hoek","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib98","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1253\/circj.CJ-15-0999","article-title":"Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations","volume":"80","author":"Tada","year":"2016","journal-title":"Circulation Journal"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib99","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L Loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib100","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib101","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib102","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib103","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib104","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/ATVBAHA.119.313877","article-title":"VLDL (Very-Low-Density Lipoprotein)-apo E (apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly","volume":"40","author":"Croyal","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol\u2010lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib106","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0021-9150(91)90187-8","article-title":"Detection and quantitation of apolipoprotein(a) mRNA in human liver and its relationship with plasma lipoprotein(a) concentration","volume":"91","author":"Wade","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib108","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1210\/jc.2019-01382","article-title":"Apolipoprotein(a) kinetics in statin-treated patients with elevated plasma lipoprotein(a) concentration","volume":"104","author":"Ma","year":"2019","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib109","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and evolving strategies to lower lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib110","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib111","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib112","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1161\/ATVBAHA.115.306136","article-title":"Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus","volume":"35","author":"Ooi","year":"2015","journal-title":"ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib113","doi-asserted-by":"crossref","first-page":"154221","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib114","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacl.2017.10.001","article-title":"Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk","volume":"12","author":"Arsenault","year":"2018","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib115","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (cholesteryl ester transfer protein) inhibition with Anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib116","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1194\/jlr.P082834","article-title":"Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects","volume":"59","author":"Nandakumar","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib117","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) may Be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib118","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib119","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib121","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib122","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13053","article-title":"Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease","volume":"49","author":"Ma","year":"2019","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib123","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-\u03b2 agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib124","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/metabo11070459","article-title":"Lipoprotein proteomics and aortic valve transcriptomics identify biological pathways linking lipoprotein(a) levels to aortic stenosis","volume":"11","author":"Bourgeois","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.atherosclerosis.2022.04.002_bib125","first-page":"4963942","article-title":"Proteomic analysis of liver from human lipoprotein(a) transgenic mice shows an oxidative stress and lipid export response","author":"Rodger","year":"2018","journal-title":"Biomed Res Int"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502200168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502200168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:49:06Z","timestamp":1758156546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502200168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":125,"alternative-id":["S002191502200168X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.002","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in demystifying the metabolism of lipoprotein(a)","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}